



IsoPlexis To Present Biomarker Data at SITC Annual Meeting

IsoPlexis will deliver two oral presentations on biomarker data captured by IsoCode, IsoPlexis' core technology.

Branford, Conn. (November 3, 2017)— IsoPlexis Corporation (IsoPlexis), a privately held life science company at the forefront of single-cell analytics technology and the immune-based cancer treatment revolution, announced today that it will deliver two oral presentations at the Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting and Pre-Conference, held November 8-12, 2017, at the Gaylord Hotel and Convention Center in National Harbor, Md.

Both presentations will highlight how data captured by IsoCode, IsoPlexis' core technology to detect cellular responses at the single-cell level, is helping to accelerate the fight against cancer. Clinical researchers at leading academic labs and biopharmaceutical companies are using IsoCode to gain a better understanding of patient response to complex immunotherapies.

During the Biomarkers Supporting Primarily T Cell Interventions Session on Wednesday, November 8, Sean Mackay, IsoPlexis' Chief Executive Officer and Co-Founder, will deliver an oral presentation that highlights "polyfunctional strength index (PSI)," a novel biomarker for predicting patient response to CAR-T and checkpoint-based therapies. PSI was developed from data captured using the IsoCode assay.

On Thursday, November 9, as part of the Workshop on Single Cell Techniques in Immunology and Cancer Immunotherapy, Mackay will deliver an oral presentation on data obtained with the IsoCode Assay, which researchers used to measure the single-cell function of tumor infiltrating lymphocytes and predict patient response for patients receiving anti PD-1 blocking therapy.

Date:	Wednesday, November 8
Time:	10:30 a.m. – 10:40 a.m.
Oral Presentation:	"Single T cell Functional Response Biomarkers to Differentiate Responders and Non-Responders in CAR-T and Checkpoint-based Cancer Immunotherapies"
Speaker:	Sean Mackay, Chief Executive Officer and Co-Founder, IsoPlexis
Date:	Thursday, November 9
Time:	1:50 p.m. – 2:15 p.m.
Oral Presentation:	Pre & Post PD-1
Speaker:	Sean Mackay, Chief Executive Officer and Co-Founder, IsoPlexis

For additional information about the conference schedule, please visit:
www.sitcancer.org/2017/home.

ABOUT ISOPLEXIS:

IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. Using a next-generation diagnostic and therapeutic platform to identify patient responses at the single-cell level, IsoPlexis' original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures, and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit <http://www.isoplexis.com> or email info@isoplexis.com.

MEDIA CONTACT:

Kate Ackerman
kackerman@gpg.com
202-292-6970